[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, tirabrutinib has shown promising efficacy for B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). In a phase I study, tirabrutinib demonstrated an overall response rate of 76.5% in patients with relapsed/refractory B-cell NHL and CLL. Additionally, tirabrutinib has been approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL). Therefore, the answer is A. yes, tirabrutinib is effective for lymphoma.\", \"answer_choice\": \"A\"}"
]